Sickle cell pain is ischemic and inflammatory pain caused by sickled red cells blocking small blood vessels, layered over time with nerve sensitization that can make pain persist between crises. For clinicians, the key point is that it is not one kind of pain. Acute vaso-occlusive episodes, chronic daily pain, and neuropathic pain each need a different approach, and patients often live with all three.
This guide sets out the mechanisms, the clinical patterns, the red flags that mimic a routine crisis, and the principles of management. For a patient-facing overview, see our article on managing sickle cell pain.
Why Sickle Cell Disease Causes Pain
Sickle cell disease results from a single point mutation in the beta-globin gene that substitutes valine for glutamic acid at position 6. The resulting hemoglobin S polymerizes when deoxygenated, distorting red cells into rigid, sickled shapes.
Vaso-occlusion is more than a mechanical plug. The pathophysiology of sickle hemoglobin involves several processes working together:
- Adhesion: sickled red cells, activated white cells, and platelets stick to the vascular endothelium, slowing flow.
- Hemolysis: sickled cells survive only about 10 to 20 days instead of the normal 120. Free hemoglobin scavenges nitric oxide and promotes vasoconstriction.
- Ischemia-reperfusion injury: repeated cycles of blocked and restored flow generate oxidative stress and tissue damage.
- Inflammation: cytokines and activated immune cells sensitize nociceptors in affected tissue.
Bone is a frequent site of pain because the marrow is a low-oxygen, slow-flow environment. Infarction within bone marrow explains the deep, boring quality of much crisis pain.
Types of Sickle Cell Pain
| Pain type | Typical features | Main drivers |
|---|---|---|
| Acute vaso-occlusive pain | Sudden onset, severe, often back, chest, limbs; lasts hours to days | Vaso-occlusion, ischemia, inflammation |
| Dactylitis (hand-foot syndrome) | Painful swelling of hands and feet in infants and young children | Infarction of small bones |
| Chronic pain | Pain on most days for more than 3 months | Tissue damage, central sensitization |
| Avascular necrosis | Hip or shoulder pain worsened by weight-bearing | Infarction of the femoral or humeral head |
| Neuropathic pain | Burning, tingling, allodynia | Peripheral and central nerve changes |
| Leg ulcers | Painful, slow-healing ulcers near the ankles | Hemolysis-related vasculopathy |
Central sensitization and chronic pain
Repeated painful episodes can remodel the nervous system. Central sensitization amplifies pain signals, producing hyperalgesia (exaggerated pain to painful stimuli) and allodynia (pain from normally harmless touch). Long-term high-dose opioid use can add opioid-induced hyperalgesia. Recognizing these patterns prevents the mistaken assumption that every flare reflects fresh vaso-occlusion.
Common Triggers
- Dehydration
- Cold exposure, wind, and swimming in cold water
- Infection and fever
- Hypoxia, including high altitude
- Physical overexertion
- Psychological stress
- Menstruation and pregnancy in some patients
Many episodes have no identifiable trigger. Genotype also matters: HbSS and HbS-beta-zero thalassemia generally carry a heavier pain burden than HbSC, though individual variation is wide.
Clinical Assessment of a Pain Episode
There is no laboratory test that confirms a vaso-occlusive episode. Diagnosis rests on the patient’s history and their own description of typical crisis pain. Patients know their disease; if they say this pain feels like their usual crisis, that is valuable information.
Diagnosis of the underlying disease is by hemoglobin electrophoresis or high-performance liquid chromatography, usually from newborn screening. During an episode, useful baseline tests include a CBC with reticulocyte count, compared with the patient’s steady-state values. In HbSS, a steady-state hemoglobin of roughly 6 to 9 g/dL is typical. A sharp fall from baseline suggests a complication rather than simple pain.
Red flags that mimic a routine crisis
- Acute chest syndrome: chest pain, fever, cough, hypoxia, or a new infiltrate on chest X-ray. It can develop during admission for limb pain.
- Splenic sequestration: abdominal pain with an enlarging spleen and a falling hemoglobin, mainly in children.
- Aplastic crisis: falling hemoglobin with a very low reticulocyte count, often from parvovirus B19.
- Osteomyelitis or septic arthritis: fever and focal bone or joint pain not following the usual pattern.
- Stroke: any new neurological deficit or severe headache.
- Priapism, cholecystitis, and hepatic sequestration: site-specific pain that needs its own management.
Managing Acute and Chronic Pain
Acute vaso-occlusive pain
- Give analgesia fast. Widely used guidelines recommend analgesia within about 60 minutes of arrival, with reassessment every 15 to 30 minutes until pain is controlled.
- Use an individualized pain plan when available, based on the patient’s previous effective doses.
- Parenteral opioids such as morphine or hydromorphone are standard for severe pain, often via patient-controlled analgesia. Meperidine (pethidine) is avoided.
- Adjuncts: NSAIDs when renal function allows, and low-dose ketamine in selected refractory cases.
- Hydrate carefully. Oral fluids first; if intravenous fluids are needed, avoid overload, which can precipitate acute chest syndrome.
- Oxygen only for hypoxemia, and incentive spirometry to reduce the risk of acute chest syndrome.
Chronic pain
Chronic pain calls for a multimodal plan: scheduled non-opioid analgesics, agents for neuropathic pain such as gabapentinoids or certain antidepressants, physical therapy, and psychological support such as cognitive behavioral therapy. Treating avascular necrosis or leg ulcers directly addresses specific pain generators.
Disease-Modifying Therapy
Hydroxyurea is the foundation. It raises fetal hemoglobin, which interferes with HbS polymerization, and reduces the frequency of pain episodes. Other options include L-glutamine and crizanlizumab. Voxelotor was withdrawn from the market in 2024, so patients previously taking it need review.
Chronic transfusion programs reduce complications in selected patients. Curative options include hematopoietic stem cell transplantation, most successful in younger patients with a matched sibling donor, and gene therapies approved in 2023 for patients aged 12 and older with recurrent vaso-occlusive episodes. Pain burden also shapes quality of life and is part of the wider discussion of the life span of sickle cell patients.
Key Takeaways
- Sickle cell pain combines ischemia, inflammation, and nervous system sensitization.
- Acute, chronic, and neuropathic pain need different strategies.
- Treat acute pain promptly and believe the patient’s description of their usual crisis.
- Always screen for acute chest syndrome, sequestration, infection, and stroke.
- Hydroxyurea reduces pain frequency and should be offered widely. More background is in our sickle cell guide.
Frequently Asked Questions
What does sickle cell pain feel like?
Patients commonly describe deep, throbbing, stabbing, or boring pain, often in the back, chest, arms, and legs. Chronic and neuropathic pain may feel burning or tingling. Intensity is frequently severe and out of proportion to visible findings.
Why do vital signs sometimes look normal during a crisis?
People who live with recurrent severe pain may not show tachycardia, hypertension, or visible distress. Normal vital signs do not exclude a genuine vaso-occlusive episode, and pain scores should rely on the patient’s report.
How long does a vaso-occlusive episode last?
Most episodes last from a few hours to several days, with some lasting a week or more. Pain that persists on most days for more than three months meets the usual definition of chronic pain.
Should all patients with a crisis receive intravenous fluids?
No. Dehydration should be corrected, preferably orally, but routine aggressive intravenous fluids offer no benefit and fluid overload can contribute to acute chest syndrome.
